Welcome to a website ofZhongnan Medical Journal Press

Recommendations

11901 recommendations found
Recommendation Strength: NoneEvidence: NoneFormal Recommendations

SGLT2i (or GLP1RA) are still the likely preferred second-line agents when escalation of metformin therapy is required (including those aged 10-17 years)—patients without cardiovascular or renal disease who are overweight or obese

Recommendation No.: 2-2024-035E-031R Guideline No.: 2-2024-035E

Categories: Treatment initiation, intensification, and adjustment, Sodium–glucose cotransporter 2 (SGLT2) inhibitors, Glucagon-like peptide 1 (GLP-1) receptor agonists and multi-receptor agonists

Recommendation Strength: NoneEvidence: NoneFormal Recommendations

The choice between an SGLT2i or GLP1RA - SGLT2i is typically preferable if renal disease or heart failure predominates (GLP1RA is preferable if CVA predominates). If the HbA1c remains above target in this high-risk group, dual SGLT2i (and GLP1RA therapy is recommended but not funded in NZ).

Recommendation No.: 2-2024-035E-030R Guideline No.: 2-2024-035E

Categories: Treatment initiation, intensification, and adjustment, Sodium–glucose cotransporter 2 (SGLT2) inhibitors, Glucagon-like peptide 1 (GLP-1) receptor agonists and multi-receptor agonists

Recommendation Strength: NoneEvidence: NoneFormal Recommendations

All patients with T2D with either diabetic renal disease OR heart failure OR CV disease OR five-year CV disease risk > 15% should ideally be on metformin, SGLT2i (and/or GLP1RA) regardless of their glycaemic control or other OHA.

Recommendation No.: 2-2024-035E-029R Guideline No.: 2-2024-035E

Categories: Sodium–glucose cotransporter 2 (SGLT2) inhibitors, Cardiovascular disease, Glycaemic targets and glucose-lowering treatment in people with chronic kidney disease

Recommendation Strength: NoneEvidence: NoneFormal Recommendations

Repeat HbA1c testing every three months with treatment intensification until the target is met; HbA1c testing is then every six months. Ideally, patients should have their blood pressure and lipids assessed at the same time, with the appropriate treatment escalating as required.

Recommendation No.: 2-2024-035E-025R Guideline No.: 2-2024-035E

Categories: HbA1c monitoring, Blood pressure targets and management of hypertension, Lipid targets and management of dyslipidaemia